PMID- 26459159
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20220408
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 109
IP  - 11
DP  - 2015 Nov
TI  - Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway 
      inflammation in patients with mild to moderate asthma.
PG  - 1391-6
LID - S0954-6111(15)30063-9 [pii]
LID - 10.1016/j.rmed.2015.09.016 [doi]
AB  - BACKGROUND: Eosinophilic airway inflammation can predict the exacerbation of 
      asthma, and we can improve the management of asthma by monitoring the 
      eosinophilic airway inflammation. Although induced sputum and sputum eosinophil 
      count is the gold standard test for diagnosing eosinophilic asthma, a more 
      accessible and receptive method is needed for clinical practice. Type 2 innate 
      lymphoid cells (ILC2) have recently been proposed to play a crucial role in 
      eosinophilic inflammation and have been identified in peripheral blood from 
      patients with asthma. OBJECTIVES: We sought to identify simple and feasible 
      biomarkers which can predict eosinophilic airway inflammation in asthmatic 
      patients. METHODS: Sputum was induced for the assessment of eosinophils in 150 
      asthmatic patients. In parallel, the proportion of ILC2s of peripheral blood 
      lymphocytes (%ILC2), blood eosinophil counts, total immunoglobulin E (IgE), 
      fractional exhaled nitric oxide (FeNO) and lung function tests were measured. 42 
      healthy donors served as controls. RESULTS: 126 patients finished sputum 
      induction and produced adequate sputum. The ILC2 level was significantly 
      increased in eosinophilic asthmatic patients compared with non-eosinophilic 
      asthmatic patients (0.117 +/- 0.090versus0.035 +/- 0.021, p < 0.001). A multiple 
      regression model, including age, sex, BMI, blood eosinophil counts, FeNO, IgE and 
      %ILC2, showed that %ILC2, blood eosinophil counts and FeNO were correlative 
      factors of sputum eosinophil counts (p < 0.001, p = 0.037, p < 0.001, 
      respectively) and %ILC2 was the most significant subset of airway eosinophilic 
      inflammation (Estimate = 11.385). A receiver operating characteristic (ROC) 
      analysis showed a sensitivity of 67.7% and a specificity of 95.3% for %ILC2 of 
      0.076 to distinguish eosinophilic asthmatic patients from non-eosinophilic 
      asthmatic patients. CONCLUSION: ILC2 is a surrogate marker of airway eosinophilic 
      inflammation in patients with mild to moderate asthma and has great potential 
      advantages for selecting the asthmatic patients most likely to benefit from 
      therapeutics targeting Th2 inflammation.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Liu, Tian
AU  - Liu T
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Wu, Jinxiang
AU  - Wu J
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Zhao, Jiping
AU  - Zhao J
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Wang, Junfei
AU  - Wang J
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Liu, Lin
AU  - Liu L
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Cao, Liuzhao
AU  - Cao L
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Liu, Yahui
AU  - Liu Y
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China.
FAU - Dong, Liang
AU  - Dong L
AD  - Dept. of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan 250012, 
      PR China. Electronic address: dl5506@126.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151009
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Biomarkers)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Asthma/*complications/immunology
MH  - Biomarkers/blood
MH  - Breath Tests/methods
MH  - Case-Control Studies
MH  - Eosinophils/pathology
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Immunity, Innate
MH  - Immunoglobulin E/blood
MH  - Leukocyte Count
MH  - Lymphocyte Subsets/*immunology
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/metabolism
MH  - Pulmonary Eosinophilia/*diagnosis/*etiology/immunology
MH  - Sputum/cytology
OTO - NOTNLM
OT  - Asthma
OT  - Biomarker
OT  - Eosinophilic inflammation
OT  - ILC2
EDAT- 2015/10/16 06:00
MHDA- 2016/09/13 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/07/31 00:00 [received]
PHST- 2015/09/27 00:00 [revised]
PHST- 2015/09/30 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
AID - S0954-6111(15)30063-9 [pii]
AID - 10.1016/j.rmed.2015.09.016 [doi]
PST - ppublish
SO  - Respir Med. 2015 Nov;109(11):1391-6. doi: 10.1016/j.rmed.2015.09.016. Epub 2015 
      Oct 9.